RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Synthesis and pharmacological validation of a novel radioligand for the orphan GPR88 receptor
Decker, A. M., Rahman, M. T., Kormos, C. M., Hesk, D., Darcq, E., Kieffer, B. L., & Jin, C. (2023). Synthesis and pharmacological validation of a novel radioligand for the orphan GPR88 receptor. Bioorganic and Medicinal Chemistry Letters, 80, 129120. Article 129120. https://doi.org/10.1016/j.bmcl.2022.129120
GPR88 is an orphan G protein-coupled receptor which has been implicated in a number of striatal-associated disorders. Herein we describe the synthesis and pharmacological characterization of the first GPR88 radioligand, [3H]RTI-33, derived from a synthetic agonist RTI-13951-33. [3H]RTI-33 has a specific activity of 83.4 Ci/mmol and showed one-site, saturable binding (KD of 85 nM) in membranes prepared from stable PPLS-HA-hGPR88-CHO cells. A competition binding assay was developed to determine binding affinities of several known GPR88 agonists. This radioligand represents a powerful tool for future mechanistic and cell-based ligand-receptor interaction studies of GPR88.
